ProShare Advisors
RLMD icon

ProShare Advisors’s Relmada Therapeutics RLMD Stock Holding History

ProShare Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.7K Buy
+12,381
New +$86.5K ﹤0.01% 1795
2022
Q4 		– Sell
-5,537
Closed -$205K – 1879
2022
Q3 		$205K Buy
+5,537
New +$153K ﹤0.01% 1398
2022
Q2 		– Sell
-7,526
Closed -$203K – 2063
2022
Q1 		$203K Buy
+7,526
New +$156K ﹤0.01% 1879
2021
Q3 		– Sell
-6,910
Closed -$221K – 2215
2021
Q2 		$221K Buy
6,910
+745
+12% +$25.9K ﹤0.01% 2094
2021
Q1 		$217K Buy
+6,165
New +$216K ﹤0.01% 1992

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ProShare Advisors's RLMD Position: Q2 2026 in Review

ProShare Advisors opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 12,381 shares worth $85.7K. The stake represents ﹤0.01% of the portfolio and ranks #1795 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in RLMD as recently as Q3 2022.

ProShare Advisors first reported a position in RLMD in Q1 2021 and has held it in 5 quarters since. The position peaked at $221K in Q2 2021. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • ProShare Advisors held 12,381 shares of Relmada Therapeutics worth $85.7K as of Q2 2026.
  • Relmada Therapeutics was a new ProShare Advisors position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1795 holding.
  • ProShare Advisors first reported a position in Relmada Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • ProShare Advisors's Relmada Therapeutics position peaked at $221K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.